Investor information

Welcome to the Investor Relations section of the Verona Pharma website

This area is dedicated to keeping shareholders and potential investors up to date with our news, share price, and other relevant information.

We are committed to delivering our strategy and creating both near-and long-term value to our shareholders.

AIM

NASDAQ

Latest press releases

  • LONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) -- TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to
  • LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that, on November 26, 2019, it granted 500,000 options to purchase ordinary shares of £0.05 each (the “Ordinary Shares”) to

Latest video

 

IR contacts

US Investor relations contact
Argot Partners
E: verona@argotpartners.com
T:+1 212-600-1902

European Investor relations contact
Optimum Strategic Communications
E: verona@optimumcomms.com
T:  +44 (0)203 950 9144